Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the thieno-thiopyran sulfonamide class. It is structurally related to dorzolamide and acts as a potent inhibitor of carbonic anhydrase 2. The drug has been studied primarily in experimental settings and has not received regulatory approval for any indication. Its primary mechanism involves inhibition of the enzyme carbonic anhydrase 2 with high affinity (Ki ≈ 1.9 nM), suggesting potential utility in conditions where modulation of this enzyme is beneficial—such as glaucoma or other disorders involving intraocular pressure—but it has not advanced beyond preclinical or early research phases[2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (4s-Trans)-4-(Methylamino)-5,6-Dihydro-6-Methyl-4h-Thieno(2,3-B)Thiopyran-2-Sulfonamide-7,7-Dioxide.